Key facts
- Truveta’s last known valuation is $1.4B (Jan 2025).
- It has raised $515.0M; the latest was Later Stage VC ($320.0M) in Jan 2025.
- Notable investors include Microsoft, Illumina, Providence Health & Services, Regeneron Pharmaceuticals.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Truveta
- ·The full record, as it builds
Funding rounds
No funding rounds for Truveta are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Truveta
Developer of a health data platform designed to aggregate data across multiple healthcare systems to provide medical information. The company's platform identifies and aggregates healthcare data, with a focus first on coronavirus, enabling researchers to find cures that allow every clinician to be an expert, and help families make the most informed decisions about their care.
- Sector
- Healthcare
- HQ
- Bellevue, WA, United States
- Founded
- 2020
- Employees
- 413
- Website
- truveta.com/
- Ownership
- Privately Held (backing)
Truveta doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Truveta shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Truveta in its N-PORT filings yet. We sweep new filings monthly.